# T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

> **NCT02153905** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Breast Cancer
- Cervical Cancer
- Renal Cancer
- Melanoma
- Bladder Cancer

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)

## Key facts

- **NCT ID:** NCT02153905
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-03
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow, insufficient accrual.
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02153905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02153905, "T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02153905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*